Cargando…

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence

Background: Currently, limited data on targeted therapy and immunotherapy sequencing in patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore, understanding the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogala, Paweł, Czarnecka, Anna M., Cybulska-Stopa, Bożena, Ostaszewski, Krzysztof, Piejko, Karolina, Ziętek, Marcin, Dziura, Robert, Rutkowska, Ewa, Galus, Łukasz, Kempa-Kamińska, Natasza, Calik, Jacek, Sałek-Zań, Agata, Zemełka, Tomasz, Bal, Wiesław, Kamycka, Agnieszka, Świtaj, Tomasz, Kamińska-Winciorek, Grażyna, Suwiński, Rafał, Mackiewicz, Jacek, Rutkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032972/
https://www.ncbi.nlm.nih.gov/pubmed/35456332
http://dx.doi.org/10.3390/jcm11082239
_version_ 1784692776681603072
author Rogala, Paweł
Czarnecka, Anna M.
Cybulska-Stopa, Bożena
Ostaszewski, Krzysztof
Piejko, Karolina
Ziętek, Marcin
Dziura, Robert
Rutkowska, Ewa
Galus, Łukasz
Kempa-Kamińska, Natasza
Calik, Jacek
Sałek-Zań, Agata
Zemełka, Tomasz
Bal, Wiesław
Kamycka, Agnieszka
Świtaj, Tomasz
Kamińska-Winciorek, Grażyna
Suwiński, Rafał
Mackiewicz, Jacek
Rutkowski, Piotr
author_facet Rogala, Paweł
Czarnecka, Anna M.
Cybulska-Stopa, Bożena
Ostaszewski, Krzysztof
Piejko, Karolina
Ziętek, Marcin
Dziura, Robert
Rutkowska, Ewa
Galus, Łukasz
Kempa-Kamińska, Natasza
Calik, Jacek
Sałek-Zań, Agata
Zemełka, Tomasz
Bal, Wiesław
Kamycka, Agnieszka
Świtaj, Tomasz
Kamińska-Winciorek, Grażyna
Suwiński, Rafał
Mackiewicz, Jacek
Rutkowski, Piotr
author_sort Rogala, Paweł
collection PubMed
description Background: Currently, limited data on targeted therapy and immunotherapy sequencing in patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore, understanding the characteristics of patients who completed sequential treatment is needed. Methods: The primary objective of this study was to analyze the efficacy of BRAFi/MEKi activity as second-line therapy in patients with advanced melanoma. We also aimed to describe the clinical characteristics of patients with advanced melanoma who were treated sequentially with immunotherapy and targeted therapy. We enrolled 97 patients treated between 1st December 2015 and 31st December 2020 with first-line immunotherapy with programmed cell death 1 (PD-1) checkpoint inhibitors; and for the second-line treatment with at least one cycle of BRAFi/MEKi therapy with follow-up through 31 January 2022. Results: Median OS since first-line treatment initiation was 19.9 months and 12.8 months since initiation of BRAFi/MEKi treatment. All BRAFi/MRKi combinations were similarly effective. Median progression free survival (PFS) was 7.5 months since initiation of any BRAFi/MEKi treatment. Conclusions: BRAFi/MEKi therapy is effective in the second-line in advanced and metastatic melanoma patients. For the first time, the efficacy of all BRAFi/MEKi combinations as second-line therapy is shown.
format Online
Article
Text
id pubmed-9032972
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90329722022-04-23 Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence Rogala, Paweł Czarnecka, Anna M. Cybulska-Stopa, Bożena Ostaszewski, Krzysztof Piejko, Karolina Ziętek, Marcin Dziura, Robert Rutkowska, Ewa Galus, Łukasz Kempa-Kamińska, Natasza Calik, Jacek Sałek-Zań, Agata Zemełka, Tomasz Bal, Wiesław Kamycka, Agnieszka Świtaj, Tomasz Kamińska-Winciorek, Grażyna Suwiński, Rafał Mackiewicz, Jacek Rutkowski, Piotr J Clin Med Article Background: Currently, limited data on targeted therapy and immunotherapy sequencing in patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore, understanding the characteristics of patients who completed sequential treatment is needed. Methods: The primary objective of this study was to analyze the efficacy of BRAFi/MEKi activity as second-line therapy in patients with advanced melanoma. We also aimed to describe the clinical characteristics of patients with advanced melanoma who were treated sequentially with immunotherapy and targeted therapy. We enrolled 97 patients treated between 1st December 2015 and 31st December 2020 with first-line immunotherapy with programmed cell death 1 (PD-1) checkpoint inhibitors; and for the second-line treatment with at least one cycle of BRAFi/MEKi therapy with follow-up through 31 January 2022. Results: Median OS since first-line treatment initiation was 19.9 months and 12.8 months since initiation of BRAFi/MEKi treatment. All BRAFi/MRKi combinations were similarly effective. Median progression free survival (PFS) was 7.5 months since initiation of any BRAFi/MEKi treatment. Conclusions: BRAFi/MEKi therapy is effective in the second-line in advanced and metastatic melanoma patients. For the first time, the efficacy of all BRAFi/MEKi combinations as second-line therapy is shown. MDPI 2022-04-17 /pmc/articles/PMC9032972/ /pubmed/35456332 http://dx.doi.org/10.3390/jcm11082239 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rogala, Paweł
Czarnecka, Anna M.
Cybulska-Stopa, Bożena
Ostaszewski, Krzysztof
Piejko, Karolina
Ziętek, Marcin
Dziura, Robert
Rutkowska, Ewa
Galus, Łukasz
Kempa-Kamińska, Natasza
Calik, Jacek
Sałek-Zań, Agata
Zemełka, Tomasz
Bal, Wiesław
Kamycka, Agnieszka
Świtaj, Tomasz
Kamińska-Winciorek, Grażyna
Suwiński, Rafał
Mackiewicz, Jacek
Rutkowski, Piotr
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
title Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
title_full Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
title_fullStr Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
title_full_unstemmed Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
title_short Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
title_sort long-term outcomes of targeted therapy after first-line immunotherapy in braf-mutated advanced cutaneous melanoma patients—real-world evidence
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032972/
https://www.ncbi.nlm.nih.gov/pubmed/35456332
http://dx.doi.org/10.3390/jcm11082239
work_keys_str_mv AT rogalapaweł longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT czarneckaannam longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT cybulskastopabozena longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT ostaszewskikrzysztof longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT piejkokarolina longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT zietekmarcin longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT dziurarobert longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT rutkowskaewa longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT galusłukasz longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT kempakaminskanatasza longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT calikjacek longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT sałekzanagata longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT zemełkatomasz longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT balwiesław longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT kamyckaagnieszka longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT switajtomasz longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT kaminskawinciorekgrazyna longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT suwinskirafał longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT mackiewiczjacek longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence
AT rutkowskipiotr longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence